There are no products in your shopping cart.
Pingclinicinc's Story Links
By Daniel Costello, Los Angeles Times Staff Writer
December 6, 2007
Genentech shares plunge. The vote could be a sign of tougher standards at the agency.
A Food and Drug Administration panel dealt a sharp blow to biotech giant Genentech Inc. on Wednesday by refusing to recommend approval for the company's high-profile drug Avastin as a treatment for breast cancer.
The news signaled to industry experts that federal regulators appear to be adopting stricter standards for drug approvals. It also sent the company's shares into free fall -- down more than 8% before trading was stopped in the afternoon.
- Login or register to post comments
- report spam









Recent Comments
2 days 17 hours ago
3 weeks 2 days ago
3 weeks 3 days ago
6 weeks 4 days ago
10 weeks 3 days ago
11 weeks 2 days ago
15 weeks 21 hours ago
16 weeks 1 day ago
18 weeks 1 day ago
19 weeks 3 days ago